Global Pharma Medicine Congress Set for Berlin in March
Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
The congress is jointly organized by the International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine (IFAPP) and the German Society of Pharmaceutical Medicine (Deutsche Gesellschaft für Pharmazeutische Medizin e.V.’ – DGPharMed).
“Drug development aiming for true innovations has become even more challenging in the past decade. The investments needed further increased, hurdles for approval and reimbursement became more demanding. In a globalized environment all economic regions are directly competing for R&D leadership in drug development,” noted the organizers, adding that the Berlin meeting will focus on the major framework conditions in that field.
The motto of the event is “The World Is Our Partner”. Beyond assessment of the status quo, the presentations will provide participants with an outlook on what it will take to stay on top of drug development. Experts will address the key topics relevant for smart development of better drugs, and there will also be exchange and networking with peers to discuss presentations and new topics.
To read the full release click here.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
